drugset / Trial / NCT05658523
COVID-19 Booster Study in Healthy Adults in Australia
Phase 3
Active not recruiting
496 enrolled
Murdoch Childrens Research Institute
Coalition for Epidemic Preparedness Innovations · collabThe Peter Doherty Institute for Infection and Immunity · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a double-blinded, randomised study to determine the safety, reactogenicity, and immunogenicity of a bivalent mRNA Moderna COVID-19 vaccine or a protein-based Novavax COVID-19 vaccine given as a fourth dose in healthy adults in Australia.
Timeline
- Start
- 2023-02-28
- Primary completion
- 2024-10-13
- Completion
- 2026-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NVX-CoV2373 | Vaccine | 5 ug | — |
| Comparator | mRNA-1273.214 | Messenger RNA (mRNA) | 25 ug | — |